FDA Approvals, News & Updates
On August 16, 2019, the FDA approved upadacitinib (Rinvoq, AbbVie), a Janus kinase inhibitor, for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
On July 24, 2019, the US Food and Drug Administration approved adalimumab-bwwd (Hadlima; Samsung Bioepis), a biosimilar to adalimumab (Humira; AbbVie) for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis.
A brief overview of new rheumatology drugs approved by the FDA between May 14, 2018, and June 1, 2018.
- Ixekizumab Approved for Adults with Psoriatic Arthritis
- Biosimilar to Infliximab Approved for All Eligible Indications of Reference Drug
- Tofacitinib and Tofacitinib Extended Release Approved for Adults with Psoriatic Arthritis
New Treatments Approved for Patients with Giant-Cell Arteritis and Moderate-to- Severe Rheumatoid Arthritis
Tocilizumab is the first therapy approved by the FDA for the treatment of adult patients with this type of vasculitis, and was granted Breakthrough Therapy designation and Priority Review for this indication.
Dr Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs, and as Senior Advisor to the FDA Commissioner.
- Adalimumab Biosimilar Approved to Treat Multiple Indications
- First Drug for Duchenne Muscular Dystrophy Granted Accelerated Approval
- FDA Approves Etanercept Biosimilar for Multiple Indications
The US Food and Drug Administration (FDA) has approved etanercept-szzs, a biosimilar to etanercept (Enbrel), for the treatment of multiple inflammatory diseases, according to an announcement by the organization. The biosimilar injection has been approved to treat patients with moderate-to-severe rheumatoid arthritis; moderate-to-severe polyarticular juvenile idiopathic arthritis; active psoriatic arthritis; active ankylosing spondylitis; and chronic, moderate-to-severe plaque psoriasis.
On May 27, 2016, the FDA approved fluciclovine F18 (Axumin; Blue Earth Diagnostics) injection, a radioactive diagnostic imaging agent used to detect recurrent prostate cancer.
On May 18, 2016, the FDA granted accelerated approval to atezolizumab (Tecentriq; Genentech) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-containing chemotherapy, or for those who have had disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Page 1 of 3
Results 1 - 10 of 28
Results 1 - 10 of 28